Abstract #LBA16; Pres time: February 16, 2023; 17:45:00 -...

Abstract #LBA16; Pres time: February 16, 2023; 17:45:00 - 18:45:00; "The inhibitory activity of Rem-L on IL-2Rα levels on activated T cells in vitro correlates with Rem-L’s in vivo bioactivity in pediatric aGVHD as indicated by reductions in circulating levels of inflammatory biomarkers and activated T cells and improved survival. Therefore, the inhibitory activity of Rem-L on T cell activation in vitro is a suitable measure of product potency in aGVHD."


”Stratifying patients in MSB-GVHD001 (n=54) by treatment with Rem-L product lots with in vitro activity of mean % IL-2Rα inhibition > median or ≤ median showed a positive association between % IL-2Rα inhibition and D180 survival (85% vs. 54%, p=0.01). This was preceded by a greater duration of the D28 OR among responders who received product with higher %IL-2Rα inhibition. The relationship between greater survival and mean % IL-2Rα inhibition > median vs ≤ median was most evident in patients with the most severe form of the disease and at highest risk for death: Minnesota high risk (D180 OS 89% vs 50%, p=0.01), MAP >0.29 (D180 OS 100% vs. 17%, p=0.003) or Grade D disease (D180 OS 91% vs. 50%, p=0.03).”

https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/22428




As I inferred …many posters on this site conveniently ignore recently prepared peer reviewed evidence. I quote from the latest breaking news poster provided in relation to Remestemcels ability to inhibit IL2Ra (CD25) which was presented at the Tandem Conference in Miami this month by Joanne Kurtzberg MD. Please note that the P value of Mesoblasts potency assay (0.003) when compared to the most acccurate validated potency assay for high risk patients …namely MAP >0.29 (ST2). Do you get the link now JB ? I think you will find that the IL2Ra potency assay is the star of the show and Mesoblast have the data to prove it . OP


Please do not rely on the facts or opinions expressed in the above post when making an investment decision.